Navigation Links
EXCEL trial will determine safety and efficacy of drug-eluting stents vs. bypass surgery
Date:3/13/2010

NEW YORK, NY AND ATLANTA, GA MARCH 13, 2010 The announcement of a new clinical trial, EXCEL (Evaluation of Xience Prime versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization), that will compare drug-eluting stents to coronary artery bypass graft surgery in patients with left main coronary artery disease, was made today at "Optimizing PCI Outcomes: Evolving Paradigms," a symposium presented by the Cardiovascular Research Foundation.

"While the SYNTAX trial suggested that percutaneous coronary intervention (PCI) with drug-eluting stents may be safe and effective in selected patients with left main coronary artery disease, the trial was not powered specifically to address this set of patients," said Gregg W. Stone, MD, Professor of Medicine at Columbia University Medical Center, Director of Cardiovascular Research and Education at the Center for Interventional Vascular Therapy at NewYork-Presbyterian Hospital/Columbia University Medical Center and Co-Director of the Medical Research and Education Division at the Cardiovascular Research Foundation.

In addition, since the SYNTAX trial, advances have been made drug-eluting stent technology, PCI procedural guidance, in bypass surgery techniques and optimal medical therapies.

"We are pleased to announce that EXCEL will address those limitations, as a landmark trial which will randomize 2,500 selected patients with left main disease," Dr. Stone said. "This trial has the appropriate magnitude, geographic representation and organization to determine the optimal revascularization strategy for patients with left main coronary artery disease."

The primary endpoint is the composite incidence of death, myocardial infarction (MI) or stroke at a median follow-up duration of 3 years, powered for sequential non-inferiority and superiority testing. The major secondary endpoint is the composite incidence of death, MI, stroke or unplanned repeat revascularization. Measures of cost-effectiveness and quality of life at several time points also constitute important secondary endpoints. All patients will be followed for a total of 5 years.

The global trial, sponsored by Abbott Vascular, will be academically organized and run by four principal investigators (including 2 cardiac surgeons and 2 interventional cardiologists), the Cardiovascular Research Foundation and Cardialysis, along with many other physician scientists. Patients will be enrolled from the United States, Canada, Europe, South America (Brazil and Argentina), and South Korea. Additional countries may be added in the future.


'/>"/>

Contact: Judy Romero
jromero@crf.org
212-851-9311
Cardiovascular Research Foundation
Source:Eurekalert

Related medicine news :

1. J.D. Power and Associates Reports: CIGNA HealthCare Recognized for Call Center Customer Satisfaction Excellence For a Second Consecutive Year
2. Best Practice Database: Complimentary Excerpt of Three Sales Force Excellence Studies
3. Massachusetts Employers and Health Plans Continue to Support Quality Care by Rewarding Physicians through Bridges to Excellence Programs
4. USC receives $7.5M for Comprehensive Center of Excellence in Minority Health
5. AAHFN President Elect Sue Wingate Received Prestigious 2007 Clinical Excellence in Nursing Award from the Heart Failure Society of America
6. Bioniche Food Safety Vaccine Receives Global Top Honours in Industry Excellence Awards
7. Insulet Awarded National Accreditation for Excellence by Community Health Accreditation Program
8. Quality Function Excellence: Is Your Money Spent Where It Matters Most?
9. Special Olympics Special Spirit in China Award Of Excellence Presented to Dedicated Friends of Special Olympics and City of Shanghai
10. NCCAM expands Centers of Excellence in CAM research program
11. Mount Sinai recognized as Center of Excellence for Research in Alzheimers disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... ... February 12, 2016 , ... Donor Network West, the organ ... Nevada, announced a partnership with San Ramon Regional Medical Center. Under the collaboration, the ... as a way to accommodate a more certain time frame for donor families for ...
(Date:2/12/2016)... ... February 12, 2016 , ... Mediaplanet today ... , The print component of “Revolutionizing Cancer Care” is distributed within the February ... and Seattle, with a circulation of approximately 250,000 copies and an estimated readership ...
(Date:2/12/2016)... ... ... US Sport Camps is pleased to announce the addition of junior golf ... the host site and directing the camps is PGA Professional and 2008 Iowa State ... recent years around Des Moines and are fortunate to have such a well-respected instructor ...
(Date:2/12/2016)... ... 2016 , ... The aging population and longer life spans ... With that, says Patrick Loughney, president of Longtree & Associates, LLC ... care environments. His company, which offers prep courses and workshops in long term ...
(Date:2/12/2016)... ... February 12, 2016 , ... With the exception of restorative dentistry, to date there has ... With the recent approval by the FDA, there is a now a new protocol in ... SDF is very simple and quick to apply. The application is as simple as ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... Feb. 12, 2016  Memorial Hermann Health System has ... Howard to bring a one-of-a-kind experience to pediatric ... cutting-edge technologies such as 360-degree video and Google Cardboard, ... then literally – giving the patients and their families ... was all caught on video . ...
(Date:2/12/2016)... 12, 2016 On Thursday, Feb. 11, 2016, ... St. David,s North Austin Medical Center successfully completed the ... Xi ® Surgical System with Trumpf Medical,s advanced ... Thiru Lakshman , M.D., colorectal surgeon at the Texas ... Integrated Table Motion technology, which seamlessly combines the da ...
(Date:2/12/2016)... 2016  Eli Lilly and Company (NYSE: LLY ) ... (pemetrexed disodium) vitamin regimen patent would not presently be infringed ... France , Italy and ... only with dextrose solution.  --> ... of Appeal held that Lilly,s patent would be indirectly infringed ...
Breaking Medicine Technology: